Canadian Health Policy – The journal of the Canadian Health Policy Institute

Canadian Health Policy Journal | CHPJ | CAN HLTH POL J | Journal of the Canadian Health Policy Institute

HIGHLIGHTS

NEWS RELEASE: National pharmacare will reduce access to new medicines for 27 million privately insured Canadians

NEWS RELEASE: Access to new medicines in Canada, Europe, and the United States: Study finds less availability and longer waits for Canadian patients

News & Announcements

NEWS RELEASE: Cost control rationale for pharmacare does not stand up to scrutiny

Audio & Video

VIDEO – Who needs National Pharmacare?

Latest Articles

State importation programs are unrealistic: diverting prescription drugs to American consumers would rapidly deplete the Canadian drug supply

Brett J Skinner, PhD | CHPI | 2024

Les programmes d’importation des États-Unis sont irréalistes : détourner les médicaments d’ordonnance vers les consommateurs américains épuiserait rapidement l’approvisionnement en médicaments au Canada

Brett J Skinner, PhD | CHPI | 2024

Government development of ‘made-in-Canada’ CAR-T cell immunotherapies: assessing cost, risk, access, and alternatives

Brett J Skinner, PhD | CHPI | 2024

Identifying Spasticity Treatment Gaps in Long-term Care and Community Settings from Ontario Real-world Evidence

Omar D. Khan, MD, FRCPC; Cathy Vo, PharmD; Huijuan Yang, Shoghag Khoudigian-Sinani; Bradley Millson, MBS; Riccardo Pedersini, PhD; Galit Kleiner, MD, FRCPC | Hotel Dieu Shaver Health and Rehabilitation Centre, Allergan, an AbbVie Company, IQVIA Solutions Canada Inc., Noesis Healthcare Technologies, Baycrest Health Sciences | 2024

Community Trust and Public Health Compliance: COVID-19 Experiences in Newfoundland and Labrador

Thaneswary Rajanderan PhD, Rodney Russell PhD, Chand S Mangat PhD, Douglas Howse BSc, Cheryl PZ Foo MD, Atanu Sarkar PhD | Memorial University NL, Infectious Diseases Research Centre Winnipeg, Government of Newfoundland and Labrador | 2024

Benefit of expedited regulatory approval for oncology drugs eliminated by slow reimbursement reviews and price negotiations

Nigel S B Rawson PhD, David J Stewart MD | University of Ottawa, Ottawa Hospital | 2024

Exploring the Ethics of Paediatric Surgical Prioritization in Canada: A Survey of Existing Institutional Guidance

Kayla Wiebe MA PhD candidate, Randi Zlotnik Shaul PhD, Simon Kelley MBChB PhD, Roxanne Kirsch MD | The Hospital for Sick Children | 2024

Effects of the COVID-19 pandemic on the number and characteristics of public drug program beneficiaries in Ontario, Canada

Z Bouck PhD, D McCormack MSc, M Tadrous PhD, J M Paterson MSc, T Campbell MPH, T Gomes PhD | St. Michael’s Hospital, University of Toronto, McMaster University | 2024

A Growing Problem: Is Canada’s Healthcare System Keeping Up with Newcomers?

Lauren Eastman BMSc MD CCFP; Sukhy K. Mahl MBA; Shoo K. Lee MBBS FRCPC PhD DHC OC | University of Alberta; University of Toronto; Mount Sinai Hospital | 2024

A Canadian Healthcare Policy Framework for Clinical Care at the End and the Beginning of Life: Prioritization, Human Resource Management, and Remuneration Models

R Douglas Wilson MD MSc FRCSC | University of Calgary | 2024

Latest Opinions

National pharmacare will reduce drug access for almost 26 million Canadians

Brett Skinner PhD | Financial Post | 2024

Controlling drug costs doesn’t require pharmacare.

Brett Skinner PhD | Financial Post | 2024

Evidence contradicts Ottawa’s cost control rationale for single-payer pharmacare.

Brett Skinner PhD | Canadian Health Policy Institute | 2024

Government hostility to biopharmaceutical industry reduces access to innovative drugs

Nigel Rawson and John Adams | Hill Times | Nov 15, 2023

Pharmacare won’t help Canadians with rare disorders

Nigel Rawson and John Adams | Financial Post | Nov 07, 2023

Canada has in fact achieved universal drug insurance coverage

Brett Skinner PhD | Toronto Star | 2023

Lower drug prices are a good thing. Canada’s approach to achieving them was not.

Nigel Rawson PhD | Globe and Mail | 2023

The drug prices review board was once a solution. It’s now a problem: Anti-drug company activists are repeating ill-informed myths about controlling drug prices in Canada

Nigel Rawson PhD and John Adams | Financial Post | 2023

For drug access, Canadians with rare disorders are 40 years behind Americans

Nigel Rawson PhD and John Adams | Financial Post | 2023

Suffer from a rare disorder in Canada? Good luck

Nigel Rawson PhD and John Adams | Financial Post | 2022

SIGN-UP for E-News and be first to know what is happening in Canadian Health Policy!

Updates on CHPI research, opinions, events and advocacy.

News & Announcements

NEWS RELEASE: National pharmacare will reduce access to new medicines for 27 million privately insured Canadians

CHPI Research | 2024

NEWS RELEASE: Access to new medicines in Canada, Europe, and the United States: Study finds less availability and longer waits for Canadian patients

CHPI Research | 2024

NEWS RELEASE: Cost control rationale for pharmacare does not stand up to scrutiny

3 March 2024

Globe and Mail, CBC, Global News cite CHPI research on cross-border re-sale risks to Canada’s drug supply

4 April 2023

Audio & Video

VIDEO – Who needs National Pharmacare?

21 AUG 2023

VIDEO – What good is National Pharmacare?

21 AUG 2023

VIDEO – Who will pay for National Pharmacare?

21 AUG 2023

AUDIO – Brett Skinner talks about dangerous new drug price regulations CFMJ AM640 Toronto

7 February 2020

AUDIO – CHPI CEO talks Pharmacare on CKLW AM800 Windsor

11 November 2019

AUDIO – GLOBAL NEWS AM770 Calgary – Danielle Smith interviews Brett Skinner about pharmacare

6 June 2019

VIDEO – National Pharmacare is unnecessary, bad for patients, and costly for taxpayers.

4 February 2019

HIGHLIGHTS

Latest Articles

Latest Opinions

SIGN-UP for E-News and be first to know what is happening in Canadian Health Policy!

News & Announcements

Audio & Video

information and ideas for better healthcare